Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
328 Leser
Artikel bewerten:
(2)

BCC Research LLC: Liquid Biopsy Market Boom: Tools, Services, and Diagnostics Unveiled

"Liquid biopsy is a revolutionary, non-invasive method for detecting diseases like cancer through blood samples instead of traditional tissue biopsies. This market is rapidly growing, offering advanced tools, services, and diagnostics that improve early detection, monitoring, and treatment decisions worldwide."

BOSTON, May 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the demand for Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets is projected to grow from $4.6 billion in 2024 to $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.

BCC Research LLC Logo

This report offers a comprehensive analysis of the global liquid biopsy market, covering tools, services, and diagnostics. It includes market trends, estimates, and CAGR forecasts from 2024 to 2029, using 2023 as the base year. The study explores industry structure, competitive dynamics, key players, product offerings, financials, and strategies. It segments the market by application, analysis purpose, biomarker type, and platform. Regional insights span North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.

Interesting facts:

  • Liquid biopsies (LBx), primarily used for genetic profiling and therapy selection, are now expanding into pharmaceutical research and enhancing various aspects of patient care.
  • Advances in nanotechnology are driving the development of innovative sensors and systems for detecting and analyzing liquid biopsy biomarkers, potentially offering greater sensitivity and specificity than existing techniques.

Factors contributing to the market's growth include:

  1. Advances in liquid biopsy workflow technologies: These are making it easier and faster to detect disease-related biomarkers in blood or other fluids. These improvements enhance accuracy, reduce processing time, and enable earlier diagnosis and better treatment monitoring.
  2. Increasing incidence of cancer: This is due to the world's aging populations, lifestyle changes, and environmental influences. This growing incidence highlights the need for better screening, early detection, and advanced treatment options.
  3. Growing awareness of early cancer detection: More people are learning about the importance of detecting cancer early, which can lead to better treatment outcomes. Awareness campaigns and improved screening methods are helping to catch cancer in its early stages.
  4. Limitations of tissue biopsy: Tissue biopsies are invasive procedures that can be painful and risky, requiring surgery or needle extraction. They may also miss tumor changes over time, making it harder to track disease progression accurately.
  5. Growing significance of precision medicine: Precision medicine tailors' treatments to a person's unique genes and disease characteristics. This approach helps improve treatment effectiveness and reduces side effects.
  6. Emerging economies: Emerging economies, such as India and Brazil, are experiencing rapid economic growth and development. Advances in the improving industries, healthcare, and infrastructure are creating new opportunities.

Request a sample copy of the global markets for liquid biopsy research tools, services and diagnostics report.

Report Synopsis

Report Metric

Details

Base year considered

2023

Forecast period considered

2024-2029

Base year market size

$3.8 billion

Market size forecast

$13.1 billion

Growth rate

CAGR of 23.3% for the forecast period of 2024-2029

Segments covered

Application, purpose of analysis, biomarker type, platform, and region

Regions covered

North America, Europe, Asia-Pacific, and the Rest of the World (South America and the Middle East and Africa)

Countries covered

U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, Japan

Market drivers

• Advances in liquid biopsy workflow technologies.

• Increasing incidence of cancer.

• Growing awareness of early cancer detection.

• Limitations of tissue biopsy.

• Growing significance of precision medicine.

• Emerging economies.

Questions addressed:

1.What is the projected market size and growth rate?

The global market for liquid biopsy research tools, services and diagnostics was estimated at $4.6 billion in 2024. It is projected to reach $13.1 billion by the end of 2029, at a CAGR of 23.3% from 2024 to 2029.

2.What segments are covered in the market?

The market segments covered include applications for cancer, and non-invasive prenatal screening. Based on biomarker type and analysis platforms, the market segments include cell free nucleic acids, circulating tumor cells, and NGS, and PCR.

3.Which application type will be dominant throughout the forecast period?

Non-invasive prenatal screening (NIPT) will be the dominant application type.

4.Which region has the largest market share?

North America holds the largest share of the market.

Market leaders include:

  • Bio-Rad Laboratories Inc.
  • Bio-Techne
  • Dxcover Ltd.
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Freenome
  • Guardant Health
  • Illumina Inc.
  • Myriad Genetics Inc.
  • Natera Inc.
  • Neogenomics Laboratories
  • Novigenix SA
  • Personalis Inc.
  • Qiagen
  • Thermo Fisher Scientific Inc.

Related reports include:

Global DNA Sequencing: Research, Applied and Clinical Markets: The global DNA sequencing market covers research, practical applications, and medical use, helping scientists study genes, develop new treatments, and diagnose diseases. As technology improves, DNA sequencing is becoming faster, more affordable, and more widely used in healthcare and research.

Exosome Diagnostics, Therapeutics and Research Tools: Global Markets: Exosome diagnostics and therapeutics involve using tiny particles released by cells to detect diseases and develop new treatments. The global market for these tools is growing as researchers explore their potential in cancer detection, drug delivery, and other medical applications.

Purchase a copy of the report direct from BCC Research.

For further information on these reports or to purchase one, please contact info@bccresearch.com.

About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype.

Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/5317069/BCC_Research_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/liquid-biopsy-market-boom-tools-services-and-diagnostics-unveiled-302454386.html

© 2025 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.